SCHEMBL337675

SCHEMBL337675

Cn1c(=O)c(C(=O)NCC(=O)OC(C)(C)C)c(O)c2cnc(N3CCCCC3)nc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.45
CALCA P06881 2/20 0.41
LMNA P02545 2/20 0.39
CASP1 P29466 1/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HIF1A Q16665 6/20 0.37
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336409 0.88 EGLN1 (0.58) EGLN1LMNACASP1HIF1A
SCHEMBL336625 0.86 EGLN1 (0.59) EGLN1LMNACASP1HIF1A
SCHEMBL2587881 0.84 CALCA (0.42) EGLN1CALCALMNAHIF1AKDM4E
SCHEMBL10084946 0.84 EGLN1 (0.44) EGLN1LMNACASP1PDE4APDE4B
SCHEMBL10084717 0.82 EGLN1 (0.45) EGLN1LMNACASP1PDE4APDE4B
SCHEMBL337574 0.82 EGLN1 (0.49) EGLN1HIF1AKMT2AMEN1NPC1
SCHEMBL337374 0.82 EGLN1 (0.49) EGLN1HIF1AKDM4EKMT2AMEN1
SCHEMBL336985 0.82 EGLN1 (0.48) EGLN1HIF1AKDM4EKMT2AMEN1
SCHEMBL337571 0.81 CALCA (0.41) EGLN1CALCALMNAHIF1AKDM4E
SCHEMBL336458 0.81 EGLN1 (0.48) EGLN1CALCAHIF1AKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN EGLN1 4/4885CALCA 3825/4885LMNA 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.